ERBB2 and cancer: Anti-cancer vaccination as a complement for standard therapy is particularly attractive in this group of patients, including those bearing TN tumors, for whom therapeutic options are limited, and for patients with HER2+ER− tumors where it may be combined with trastuzumab.